SYRE Reports $463M Offering Proceeds, $1.2B Pro Forma Cash, SKYLINE Phase 2 Topline in Q3 2026, RA Sub-Study Accelerated
Spyre Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $70.54
+6.5% in 7d after detection
Post-detection moves
1h
—
1d
+2.8%
3d
+5.7%
7d
+6.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS